TD Cowen Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Core Viewpoint - Legend Biotech Corporation (NASDAQ:LEGN) is recognized as a promising biotech stock, with a Buy rating maintained by TD Cowen analyst Yaron Werber and a price target set at $62.00 [1][2]. Company Growth Potential - The optimistic rating is supported by the company's future growth potential and strategic positioning, despite current supply constraints with its Carvykti product [2]. - Management is confident in overcoming these supply limitations by the end of 2025, aided by planned capacity expansions at key sites [2]. Financial Expectations - Legend Biotech Corporation anticipates meeting the consensus sales target of $1.9 billion for the fiscal year 2025 [3]. Company Operations - The company is a clinical-stage entity focused on developing, discovering, manufacturing, and commercializing novel therapies for oncology and other indications [3]. - It operates advanced cell therapies across a diverse range of technology platforms and has a presence in the US, China, and other geographical segments [4].